The onset of CRS following CAR T-cell infusion is variable and related to dose level with primary symptom of fever, which may be affected by increased use of tocilizumab in the EI cohort. (A) Swimmer plot of time to onset of CRS and its severity and duration (gray, no CRS; yellow, mild CRS; red, sCRS), with administration of tocilizumab (arrowheads) and dexamethasone (asterisks), as well as annotation for the assigned intervention cohort (DLT and EI; y-axis). (B) The onset of CRS by dose level of CAR T cells, as well as the severity of CRS by dose level (gray, mild CRS; red, sCRS). (C) Maximum fever following CAR T-cell infusion through day +28 grouped based on the presence or absence of sCRS. (D) Maximum fever based on CRS severity in the DLT cohort (D) and the EI cohort (E). *P < .05, **P  ≤  .01. NS, not significant.